Physician profile
Ruby Meyer
NPI 1730799651
$2,245.13
in general payments reported to CMS, 2019-2025
20 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.60 · 2022: $39.46 · 2023: $416 · 2024: $331 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425 · Travel and Lodging: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.74 |
| Travel and Lodging | $761.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $908.82 | 2025 | Interstim |
| Astrazeneca Pharmaceuticals Lp | $169.66 | 2023-2025 | Fasenra, Farxiga, Airsupra |
| Gilead Sciences, INC. | $165.84 | 2021-2023 | Descovy |
| Viiv Healthcare Company | $151.55 | 2024-2025 | Apretude |
| Grifols USA, LLC | $128.25 | 2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.64 | 2023-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $75.10 | 2024-2025 | |
| Lilly USA, LLC | $74.27 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $67.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ferring Pharmaceuticals INC. | $61.06 | 2025 | Adstiladrin |
| Dexcom, INC. | $54.38 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $54.23 | 2025 | |
| Sumitomo Pharma America, INC. | $39.21 | 2025 | Orgovyx |
| Urogen Pharma, INC. | $35.22 | 2025 | |
| Pfizer INC. | $31.64 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.07 | 2025 | Repatha |
| Olympus America INC. | $27.91 | 2025 | Itind System |
| Antares Pharma, INC. | $16.66 | 2025 | Xyosted |
| Astellas Pharma US INC | $15.00 | 2025 | Xtandi |
| Horizon Therapeutics Plc | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.